In addition to an extensive library of clinical pharmaceutical data, we possess an intellectual property portfolio containing six issued patents (five in U.S. and one in Taiwan) and a registered trademark, in the U.S. The sixth and newest patent, "Treatment of Thrombocytopenia Using Orally Administered Interferon", was issued on July 21, 2017, and will expire in 2033. The scientific proof for this patent came out of a clinical trial conducted between 2009 and 2012. This trial was designed to use low-dose oral interferon to help prevent viral recurrence in hepatitis C patients who have received the combination conventional therapy high-dose injectable interferon-α and ribavirin. As a result of receiving conventional therapy, numerous patients suffered thrombocytopenia. Surprisingly, platelet counts of the treatment group in which patients received 500IU (international units) of low-dose oral interferon daily, quickly recovered back to the normal range of platelet count within 4 weeks and these patients experienced almost no adverse side effects. In technical terms, the results were highly statistically significant (p = 0.003). This discovery signaled the beginning of a potential product that could be utilized to treat thrombocytopenia. We intend to apply our core technology, low-dose oral interferon (IFN-α), to treat the effects of this prolific and serious condition. The Company has successfully filed two Continuation Applications with the U.S. Patent Trademark Office (USPTO) that will broaden the patent coverage to include a method of reducing the rate of hepatitis C recurrence in patients (including those patients also suffering from thrombocytopenia).